Hymowitz v. Eli Lilly & Co.

136 Misc. 2d 482, 518 N.Y.S.2d 996, 1987 N.Y. Misc. LEXIS 2476
CourtNew York Supreme Court
DecidedJuly 16, 1987
StatusPublished
Cited by8 cases

This text of 136 Misc. 2d 482 (Hymowitz v. Eli Lilly & Co.) is published on Counsel Stack Legal Research, covering New York Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hymowitz v. Eli Lilly & Co., 136 Misc. 2d 482, 518 N.Y.S.2d 996, 1987 N.Y. Misc. LEXIS 2476 (N.Y. Super. Ct. 1987).

Opinion

OPINION OF THE COURT

Ira Gammerman, J.

In this pharmaceutical product liability action, plaintiff [483]*483Mindy Hymdwitz alleges that she developed cancer as a result of prenatal exposure to diethylstilbestrol (DES), a synthetic estrogen taken by her mother in 1954 during pregnancy to prevent possible miscarriage.

Plaintiff was born on December 11, 1954. The cancerous condition for which plaintiff seeks damages allegedly appeared in 1979. Under the Statute of Limitations then applicable (CPLR 208, 214), plaintiff was barred from commencing suit in December 1975 (three years after reaching the age of majority). Plaintiff brings this action, however, under the provisions of the 1986 revival statute (L 1986, ch 682, § 4).

Plaintiff moves pursuant to CPLR 3212 to strike affirmative defenses raised by some defendants challenging the constitutionality of the revival statute and alleging that the action is time barred under the Statute of Limitations otherwise applicable.

Defendants Eli Lilly and Co. (Lilly), Abbott Laboratories (Abbott) and the Upjohn Company (Upjohn) seek summary judgment and dismissal of the complaint as barred by the Statute of Limitations absent the availability of the allegedly unconstitutional revival statute.

Defendant E. R. Squibb & Sons (Squibb) opposes the relief sought by plaintiff and contends that before the issue of the constitutionality of the revival statute is determined further discovery is required on the issue of whether such extraordinary circumstances exist in this case to justify invocation of the statute which Squibb also contends is unconstitutional. (Squibb further urges that discovery is needed to determine whether plaintiff can identify the manufacturer of the DES actually taken by her mother.)

The revival portion of the 1986 tort reform legislation provides that actions seeking damages for personal injury, property damage or death caused by the latent effects of exposure to five substances (DEC, asbestos, tungsten-carbide, chlordane and polyvinylchloride) that were time barred or dismissed, as of the effective date of the statute, may be instituted "within one year from the effective date of this act”. (L 1986, ch 682, § 4.) The statute was passed on July 1, 1986 and was signed by the Governor on July 30, 1986.

In addition to the revival provision for the five specified substances (§ 4), the new tort reform legislation adopted a general discovery-based Statute of Limitations for injuries caused by latent effects of exposure to any substance (CPLR 214-c [2]). Under subdivision (2), a victim may assert a cause of action within three years from the date the injury was or should have been discovered.

[484]*484The provision for revival of claims (§ 4) and the discovery-based Statute of Limitations (L 1986, ch 682, § 2) were intended by the Legislature to remedy the perceived injustice caused by the application of CPLR 214, 208 (the exposure-based Statute of Limitations) and to provide legal recourse for injuries caused by latent effects of toxic substances. Both provisions were enacted to remedy the failure of the old statute to recognize that such injuries may not appear until years after exposure, long after the expiration of the period within which actions may be instituted.

Legislative history indicates that the five named substances were distinguished from other toxic substances (§ 2) as a result of compromise between the Assembly (which had voted to permit revival for all toxic substances) and the Senate which wanted to limit revival. The Legislature ultimately limited revival based upon the existence of an identifiable group affected and the resulting ability to predict the future costs of such revival. The Legislature was apparently concerned that under a broader revival statute, the large number of unknown victims would create unpredictable risks and costs.

Defendants challenge the revival statute on equal protection and due process grounds, arguing that the statute is the result of an arbitrary and irrational political arrangement arrived at without rational guidelines of scientific certainty or public necessity. Defendants further argue that the legislative concern for limiting the number of potential claimants and costs is not related to the ostensible objective of the legislation, i.e., to allow victims of latent injuries to maintain actions. Defendants contend that the revival provision must be stricken on equal protection grounds, as an underinclusive random penalty without scientific basis, on five arbitrarily chosen substances and their manufacturers. It is contended that the prior exposure Statute of Limitations or the new three-year discovery-based provision would be more than adequate for victims of the five specified substances.

Defendant Lilly urges that generally, chemical injury claims accrue at the time of exposure (here, in útero). Under the three-year exposure-based Statute of Limitations (tolled to the age of majority) claimants could bring suit until age 21. Lilly contends that most DES patients develop cancer by age 19, and, therefore, their claims would not be time barred before becoming aware of their injuries.

Defendants also claim a violation of the Due Process Clause, in that the statute constitutes an arbitrary deprivation of the substantive property right to rely upon the absence of claims. [485]*485Defendants assert that dismissal (or the passage of the applicable time bar) gives rise to substantive property rights which as a general rule may not be abrogated and that the exceptional circumstances to permit revival are not present (see, Gallewski v Hentz & Co., 301 NY 164).

Based upon the impact upon what they allege are substantive or property rights, defendants urge the applicability of strict scrutiny or an intermediate standard of review rather than a rational basis examination.

As a general rule, State Statutes of Limitation reviving time-barred actions are not violative of due process. Statutes of Limitation represent a public policy statement with respect to the privilege to litigate. "[T]he history of pleas of limitation shows them to be good only by legislative grace and to be subject to a relatively large degree of legislative control” (Chase Sec. Corp. v Donaldson, 325 US 304, 314). The expiration of the applicable time period does not eliminate a cause of action but rather suspends the court’s power to grant a remedy (Hulbert v Clark, 128 NY 295). In other words, Statutes of Limitation relate to the availability of a remedy and not to the destruction of any fundamental right.

In the past, New York courts have upheld the power of the State Legislature to extend or revive time-barred claims. In Gallewski v Hentz & Co. (301 NY 164, 174, supra), the court found that a revival statute is not necessarily void as a taking of property without due process. The court stated (at 174) that "[T]he Legislature may constitutionally revive a personal cause of action where the circumstances are exceptional and are such as to satisfy the court that serious injustice would result to plaintiffs not guilty of any fault if the intention of the Legislature were not effected.”

In Matter of McCann v Walsh Constr. Co. (282 App Div 444, affd 306 NY 904), the court found that the Legislature acted within the limits of the Constitution in extending the time period within which victims of caisson disease could seek redress.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Singer v. Eli Lilly & Co.
153 A.D.2d 210 (Appellate Division of the Supreme Court of New York, 1990)
McGowan v. New York Telephone Co.
144 Misc. 2d 625 (New York Supreme Court, 1989)
Besser v. E. R. Squibb & Sons, Inc.
146 A.D.2d 107 (Appellate Division of the Supreme Court of New York, 1989)
Hymowitz v. Eli Lilly & Co.
139 A.D.2d 437 (Appellate Division of the Supreme Court of New York, 1988)
Burdick v. Afrimet-Indussa Inc.
138 Misc. 2d 598 (New York Supreme Court, 1988)

Cite This Page — Counsel Stack

Bluebook (online)
136 Misc. 2d 482, 518 N.Y.S.2d 996, 1987 N.Y. Misc. LEXIS 2476, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hymowitz-v-eli-lilly-co-nysupct-1987.